Broad-spectrum activity of bulevirtide against clinical isolates of HDV and recombinant pan-genotypic combinations of HBV/HDV

Background & Aims: Bulevirtide (BLV) is a small lipopeptide agent that specifically binds to the sodium taurocholate cotransporting polypeptide (NTCP) bile salt transporter and HBV/HDV receptor on the surface of human hepatocytes and inhibits HDV and HBV entry. As a satellite virus of HBV, H...

Full description

Bibliographic Details
Published in:	JHEP Reports
Main Authors:	Roberto Mateo, Simin Xu, Alex Shornikov, Tahmineh Yazdi, Yang Liu, Lindsey May, Bin Han, Dong Han, Ross Martin, Savrina Manhas, Christopher Richards, Caleb Marceau, Thomas Aeschbacher, Silvia Chang, Dmitry Manuilov, Julius Hollnberger, Stephan Urban, Tarik Asselah, Dzhamal Abdurakhmanov, Pietro Lampertico, Evguenia Maiorova, Hongmei Mo
Format:	Article
Language:	English
Published:	Elsevier 2023-11-01
Subjects:	hepatitis delta virus hepatitis Bulevirtide
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589555923002240

Similar Items

Comparing methods for plasma HDV RNA quantification in bulevirtide-treated and untreated patients with HDV
by: Maria Paola Anolli, et al.
Published: (2025-03-01)

Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide
by: Selma El Messaoudi, et al.
Published: (2024-08-01)

Modelling HDV kinetics under the entry inhibitor bulevirtide suggests the existence of two HDV-infected cell populations
by: Louis Shekhtman, et al.
Published: (2024-02-01)

A Review of HDV Infection
by: Gian Paolo Caviglia, et al.
Published: (2022-08-01)

Clinical and Pathophysiological Considerations Related to the Impact of Bulevirtide, a New Entry Inhibitor, in HBV-HDV Infection
by: Raisa Eloise Barbu, et al.
Published: (2026-04-01)

Is Combined Bulevirtide and Pegylated Interferon Therapy for Chronic Hepatitis D Superior over Bulevirtide Monotherapy?
by: V. E. Syutkin, et al.
Published: (2020-09-01)

Modeling the Interplay between HDV and HBV in Chronic HDV/HBV Patients
by: Adequate Mhlanga, et al.
Published: (2022-10-01)

Treatment of Chronic Hepatitis D with Bulevirtide—A Fight against Two Foes—An Update
by: Peter Ferenci, et al.
Published: (2022-11-01)

Molecular and Clinical Features of Hepatocellular Carcinoma in Patients with HBV-HDV Infection
by: Costante F, et al.
Published: (2023-04-01)

Bulevirtide plus Tenofovir Disoproxil Fumarate Improves Liver Function in HDV/HBV Related Cirrhosis after Virological Response: A Case Report
by: Nikolaos Papadopoulos, et al.
Published: (2022-10-01)

Treating hepatitis D with bulevirtide – Real-world experience from 114 patients
by: Christopher Dietz-Fricke, et al.
Published: (2023-04-01)

Improving Virological Monitoring of HDV Infection: A Proof-of-Concept Comparative Study of Bosphore and AltoStar<sup>®</sup> Assays in Patients Treated with Bulevirtide
by: Verdiana Zulian, et al.
Published: (2025-06-01)

Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression
by: Mathias Jachs, et al.
Published: (2023-08-01)

Prevalence of HDV infection in people living with HIV: Data from a multicenter Italian cohort
by: Laura Ambra Nicolini, et al.
Published: (2023-01-01)

A Mathematical Model for Early HBV and -HDV Kinetics during Anti-HDV Treatment
by: Rami Zakh, et al.
Published: (2021-12-01)

Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection
by: Toni Herta, et al.
Published: (2022-04-01)

Characterization of the Full-Length Genome Sequences and Phylogenetic Analysis of HDV Strains Isolated from Patients with Chronic HBV and HDV Infection in Kyrgyz Republic
by: Yu. V. Ostankova, et al.
Published: (2020-04-01)

Clinical profile and parameters of patients monoinfected with HBV and infected with HDV in Western Amazon
by: Eugênia de Castro e Silva, et al.
Published: (2024-05-01)

Response-guided bulevirtide ± pegylated interferon alfa-2a: Long-term outcomes observed in the nationwide Austrian hepatitis D cohort study
by: Michael Schwarz, et al.
Published: (2026-06-01)

Chronic HDV Infection Shows Higher HBsAg Isoform Levels than HBV Infection, Paralleling HDV Replicative Activity
by: Stefano D’Anna, et al.
Published: (2026-04-01)

Clinical Pharmacology of Bulevirtide: Focus on Known and Potential Drug–Drug Interactions
by: Martina Billi, et al.
Published: (2025-02-01)

A human monoclonal antibody against HBsAg for the prevention and treatment of chronic HBV and HDV infection
by: Rani Burm, et al.
Published: (2023-03-01)

HBV, HCV, and HDV Triple-Infection—A Therapeutic Challenge
by: Alexia Anastasia Stefania Balta, et al.
Published: (2025-05-01)

Predominance of HBV Genotype B and HDV Genotype 1 in Vietnamese Patients with Chronic Hepatitis
by: Nghiem Xuan Hoan, et al.
Published: (2021-02-01)

Prevalence of HDV, HCV, and HIV Infection in the Population of Patients Infected with HBV in a Romanian Cohort
by: Antoanela Curici, et al.
Published: (2025-01-01)

Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
by: Janine Hartl, et al.
Published: (2012-07-01)

HBV/HDV Co-Infection: Epidemiological and Clinical Changes, Recent Knowledge and Future Challenges
by: Caterina Sagnelli, et al.
Published: (2021-02-01)

HDV Pathogenesis: Unravelling Ariadne’s Thread
by: Eirini D. Tseligka, et al.
Published: (2021-04-01)

Assessment of Response and Safety of Bulevirtide Treatment in Patients with Chronic Delta Virus Infection: The ARISTOTLE Pilot Observational Study
by: Luca Rinaldi, et al.
Published: (2025-02-01)

Constraint of Base Pairing on HDV Genome Evolution
by: Saki Nagata, et al.
Published: (2021-11-01)

Discontinuation of Passive Immunization Is Safe after Liver Transplantation for Combined HBV/HDV Infection
by: Ramin Raul Ossami Saidy, et al.
Published: (2021-05-01)

Lack of Tissue Virological Response as a Predictor of Relapse in Chronic Hepatitis D after Completion Bulevirtide Therapy
by: P. O. Bogomolov, et al.
Published: (2024-12-01)

HBV COVALENTLY CLOSED CIRCULAR DNA AS A MARKER OF PREVALENCE OF OCCULT HEPATITIS В IN PATIENTS WITH HBV, HDV AND HCV INFECTION IN UZBEKISTAN
by: A. V. Semenov, et al.
Published: (2016-10-01)

Cost-Effective Synthesis of Bule-OH: An Alternative to Bulevirtide for Hepatitis B and D Research
by: Hongxiang Zhu, et al.
Published: (2025-06-01)

Rapid suppression of HBV replication before related liver transplantation in a patient with HDV superinfection. Clinical case report
by: U. R. Salimov, et al.
Published: (2024-09-01)

Inhibitory Effect of IL-1β on HBV and HDV Replication and HBs Antigen-Dependent Modulation of Its Secretion by Macrophages
by: Marion Delphin, et al.
Published: (2021-12-01)

Detection of circulating HBV QSA3/E recombinants and HDV genotype GT5 amongst blood donors in Senegal
by: Tiffany Fortney, et al.
Published: (2026-06-01)

An ELISA method using serum derived HDAg for the sorological detection of HDV antigens and antibodies
by: Celso Granato, et al.
Published: (1987-12-01)

Intrinsic Immune Response of HBV/HDV-Infected Cells and Corresponding Innate (Like) Immune Cell Activation
by: Christopher Groth, et al.
Published: (2024-11-01)

Prevalence of HDV infections in Poland based on the experience of a single center in Silesia and literature research
by: Aleksandra Włosowicz, et al.
Published: (2024-06-01)